+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05408845

Comparing Ado-Trastuzumab Emtansine With Chemotherapy Plus Trastuzumab and Trastuzumab Deruxtecan in Treating HER2-Expressing Recurrent or Metastatic Salivary Gland Cancer

Led by NRG Oncology · Updated on 2026-10-23

146

Participants Needed

154

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

This research evaluates targeted therapies for patients with HER2-expressing salivary gland cancer that is recurrent, has spread to other parts of the body, or cannot be removed by surgery. It compares the usual treatment of chemotherapy with docetaxel plus trastuzumab against ado-trastuzumab emtansine T-DM1 in patients with HER2-positive cancer. It also studies how trastuzumab deruxtecan works in patients with HER2-low expressing salivary gland cancer. The study aims to understand which treatment may better control cancer growth and improve survival. Participants are assigned to different treatment groups based on their HER2 status. Those with HER2-positive cancer are randomly assigned to receive either docetaxel plus trastuzumab every 21 days for up to 6 cycles or ado-trastuzumab emtansine every 21 days until progression or toxicity. Patients with HER2-low expressing cancer receive trastuzumab deruxtecan every 21 days. Treatments are given intravenously, and patients may cross over to the other treatment if their disease progresses. Imaging scans, heart function tests, blood samples, and biopsies occur during screening and treatment. Throughout the study, participants undergo regular assessments including CT or MRI scans and heart evaluations to monitor cancer status and treatment effects. Blood samples and biopsies help researchers study the cancers biology. After treatment ends, patients are followed up every 3 months for 2 years, then every 6 months for an additional 3 to 5 years, and then annually to track long-term outcomes. Researchers measure progression-free survival and response rates to evaluate treatment impact.

CONDITIONS

Brief Title

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here